SeaStar Medical (NASDAQ:ICU) Raised to “Hold” at Wall Street Zen

SeaStar Medical (NASDAQ:ICU) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

SeaStar Medical Price Performance

NASDAQ ICU opened at $3.54 on Friday. SeaStar Medical has a twelve month low of $2.07 and a twelve month high of $12.50. The firm has a market capitalization of $15.61 million, a PE ratio of -0.91 and a beta of -1.05. The stock’s 50 day moving average is $3.39 and its 200 day moving average is $3.54.

SeaStar Medical (NASDAQ:ICU) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.06. The company had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.49 million. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%. On average, research analysts anticipate that SeaStar Medical will post -3.66 earnings per share for the current year.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation (NASDAQ: ICU) is a medical technology company focused on developing therapies that address excessive inflammation and immune-system activation in critically ill patients. The company’s approach is designed to target activated immune cells in the bloodstream, which can contribute to organ damage and complications associated with severe illness.

SeaStar Medical’s lead product is Quelimmune, formerly known as the Selective Cytopheretic Device (SCD). The extracorporeal blood-purification device is used with continuous kidney replacement therapy to selectively target pro-inflammatory cells while blood circulates outside the body.